AIM IMMUNOTECH INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
AIM IMMUNOTECH INC. (AIM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-27
- AIM IMMUNOTECH INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -0.90%.
- AIM IMMUNOTECH INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 4.65%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -0.90% 10-K · filed 2026-03-27 |
| 2023-12-31 | 4.65% 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |